Literature DB >> 20645410

Spinal cord injury induces differential expression of the profibrotic semaphorin 7A in the developing and mature glial scar.

Marcel A Kopp1, Benedikt Brommer, Nicole Gatzemeier, Jan M Schwab, Harald Prüss.   

Abstract

Semaphorin 7A (Sema7A) is involved in the formation of the central nervous system during development by operating axon guidance and neuronal migration. We investigated the expression of the TGFβ-inducible Sema7A following spinal cord injury (SCI). After SCI, Sema7A(+) cells accumulated specifically in lesion areas resulting in significantly enhanced Sema7A expression at the injury site (P < 0.0001). During the first days lesional Sema7A expression was confined to neurons, ballooned neurite fibers/retraction bulbs, and endothelial cells. At day 7, we observed Sema7A expression by components of the glial scar, such as reactive astrocytes and pronounced extracellular Sema7A deposition. In the direct perilesional rim, Sema7A(+) astrocytes coexpressed the activation-associated intermediate filament vimentin. In the injured spinal cord, numbers of Sema7A(+) cells reached maximum levels at day 14. The restricted accumulation of Sema7A(+) reactive astrocytes and Sema7A deposition in fibronectin(+) extracellular matrix territories suggests a participation of the fibrostimulatory Sema7A in the developing and maturating scar following SCI. In addition, Sema7A appears to be marker a for astrocyte activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20645410     DOI: 10.1002/glia.21045

Source DB:  PubMed          Journal:  Glia        ISSN: 0894-1491            Impact factor:   7.452


  11 in total

1.  The regulation of Sox2 and Sox9 stimulated by ATP in spinal cord astrocytes.

Authors:  Maosheng Xia; Yue Zhu
Journal:  J Mol Neurosci       Date:  2014-08-13       Impact factor: 3.444

2.  Semaphorin 7A modulates cytokine-induced memory-like responses by human natural killer cells.

Authors:  Joshua Ghofrani; Olivier Lucar; Haley Dugan; R Keith Reeves; Stephanie Jost
Journal:  Eur J Immunol       Date:  2019-05-02       Impact factor: 5.532

3.  Semaphorin 7A as a Potential Therapeutic Target for Multiple Sclerosis.

Authors:  Ana Gutiérrez-Franco; Herena Eixarch; Carme Costa; Vanessa Gil; Mireia Castillo; Laura Calvo-Barreiro; Xavier Montalban; José A Del Río; Carmen Espejo
Journal:  Mol Neurobiol       Date:  2016-10-06       Impact factor: 5.590

4.  Endogenous TGFβ1 Plays a Crucial Role in Functional Recovery After Traumatic Brain Injury Associated with Smad3 Signal in Rats.

Authors:  Xu-Yang Wang; Ying-Chun Ba; Liu-Lin Xiong; Xiao-Li Li; Yu Zou; Ye-Chun Zhu; Xin-Fu Zhou; Ting-Hua Wang; Fang Wang; Heng-Li Tian; Jin-Tao Li
Journal:  Neurochem Res       Date:  2015-08-08       Impact factor: 3.996

Review 5.  Semaphorin7A: branching beyond axonal guidance and into immunity.

Authors:  Ramon Garcia-Areas; Stephania Libreros; Vijaya Iragavarapu-Charyulu
Journal:  Immunol Res       Date:  2013-12       Impact factor: 2.829

Review 6.  Tripartite synaptomics: Cell-surface proximity labeling in vivo.

Authors:  Tetsuya Takano; Scott H Soderling
Journal:  Neurosci Res       Date:  2021-05-19       Impact factor: 3.304

7.  Studies of postpartum mammary gland involution reveal novel pro-metastatic mechanisms.

Authors:  Taylor R Wallace; Sarah E Tarullo; Lyndsey S Crump; Traci R Lyons
Journal:  J Cancer Metastasis Treat       Date:  2019-02-19

8.  Abundant expression of guidance and synaptogenic molecules in the injured spinal cord.

Authors:  Anne Jacobi; Anja Schmalz; Florence M Bareyre
Journal:  PLoS One       Date:  2014-02-11       Impact factor: 3.240

9.  Quantification of dendritic and axonal growth after injury to the auditory system of the adult cricket Gryllus bimaculatus.

Authors:  Alexandra Pfister; Amy Johnson; Olaf Ellers; Hadley W Horch
Journal:  Front Physiol       Date:  2013-08-23       Impact factor: 4.566

Review 10.  Semaphorins in Angiogenesis and Autoimmune Diseases: Therapeutic Targets?

Authors:  Vijaya Iragavarapu-Charyulu; Ewa Wojcikiewicz; Alexandra Urdaneta
Journal:  Front Immunol       Date:  2020-03-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.